Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics, Inc. (STOK) is a healthcare company (biotechnology) based in the United States. The share price is $26.36, down 1.01% on the day, which values the company at $1.72B. Price as of 17 Nov 2026, 17:28 UTC, from Yahoo Finance.

Key facts

Share price
$26.36−1.01% today
Market value
$1.72B
Funk Score
69/100
Against its own history
Well below its usual priceusual price $40.95
200-week average
$16.3262% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Stoke Therapeutics, Inc. in more detail

STOK trades at -6.5× next year's expected earnings, 61.1× sales. Measured against its own history, the price is 36% below what its usual multiples would imply ($40.95) — well below its usual price. It sits 62% above its 200-week average of $16.32.

Its Funk Score is 69 out of 100 (financial strength 8.8, profitability 4.0, growth 8.3, value 6.4, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Heavy stock-based pay.

1 of the superinvestors tracked here hold STOK, including Julian and Felix Baker (0.5% of the portfolio).

Superinvestors holding STOK

1 of the investors tracked here report a position in their latest 13F filing.

Stoke Therapeutics, Inc. (STOK): questions and answers

What is Stoke Therapeutics, Inc.'s market cap?

Stoke Therapeutics, Inc. is valued at $1.72B at a share price of $26.36.

Is STOK overvalued or undervalued?

Against its own history, STOK is well below its usual price: the price is 36% below the $40.95 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is STOK above its 200-week moving average?

Yes. STOK is 61.5% above its 200-week average of $16.32. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Stoke Therapeutics, Inc. growing?

Over the last three fiscal years Stoke Therapeutics, Inc.'s revenue grew 145.9% a year.

Does STOK pay a dividend?

Stoke Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own STOK?

In their latest quarterly filings, Julian and Felix Baker (0.5% of the portfolio) hold STOK. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Stoke Therapeutics, Inc. (STOK) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/STOK

Underlying data: Yahoo Finance; company filings with the SEC.